SARS-CoV-2-IN-31 

SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC₅₀ values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer^[1].

IC50: 38.36 μM (MCF-7); 38.46 μM (MDA-MB-231); 28.84 μM (HeLa); 30.62 μM (PC-3); ＞40 μM (Ishikawa)^[1]

SARS-CoV-2-IN-31 exhibits antiproliferative activity in five different human cancer cell lines with IC₅₀ values of 38.36 μM (MCF-7), 38.46 μM (MDA-MB-231), 28.84 μM (HeLa), 30.62 μM (PC-3) and ＞40 μM (Ishikawa), respectively^[1].
SARS-CoV-2-IN-31 shows comparatively high binding affinity with value of -8.3 Kcal/mole^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

464.56

C₂₉H₂₈N₄O₂

1017691-52-9

OC1=C(C(C2=C(N(C3=CC=CC=C3)N=C2C)O)C4=CC=C(CC)C=C4)C(C)=NN1C5=CC=CC=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Anamika Gupta, et al. Visible Light-Promoted Green and Sustainable Approach for One-Pot Synthesis of 4,4’-(Arylmethylene)bis(1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. ACS Omega 2022.